jilipark vip
Primary Hyperoxaluria Therapeutics Market Size in the 7MM was ~USD 316 million in 2023, estimated DelveInsight 12-23-2024 11:20 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Discover Key Insights into the Primary Hyperoxaluria Market with DelveInsight's In-Depth Report @ Primary Hyperoxaluria Market Size [ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from Primary Hyperoxaluria Market Report * In the assessment done by DelveInsight, the estimated total prevalent cases of Primary Hyperoxaluria in the 7MM were ~12 thousand in 2023. * The highest total diagnosed prevalent cases of Primary Hyperoxaluria were accounted by US in 2023 (~2 thousand), which are expected to show a rise in the future. * Among the European countries, the UK had the highest diagnosed prevalent cases of Primary Hyperoxaluria with ~220 cases, followed by Germany, which had prevalent population of ~188 in 2023. On the other hand, Spain had the lowest prevalent population (~100 cases). * Japan had the fewest total diagnosed prevalent cases of Primary Hyperoxaluria in 2023, accounting for approximately 2.5% of the cases in 7MM. * In 2023, in the US, the age-specific diagnosed prevalent cases of Primary Hyperoxaluria were highest for age group 0-4 (~780 cases), followed by 5-9 (~470 cases). The lowest number of cases was in the 15-19 years age group. * In 2023, in Japan, the type-specific diagnosed prevalent cases of Primary Hyperoxaluria were highest for Primary Hyperoxaluria Type 1 (~64 cases), followed by Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3 and unclassified. * The leading Primary Hyperoxaluria Companies such as Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Biocodex, Dicerna Pharmaceuticals , and others * Promising Primary Hyperoxaluria Therapies such as Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, Lumasiran, stiripentol (Diacomit), DCR-PHXC , and others Navigate the complexities of the Primary Hyperoxaluria Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Primary Hyperoxaluria Market Forecast. Click here to get more insights @ Primary Hyperoxaluria Treatment Market [ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Primary Hyperoxaluria Epidemiology Segmentation in the 7MM * Prevalent Cases of Primary Hyperoxaluria in the 7MM * Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM * Gender-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM * Age-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM * Type-specific Cases of Diagnosed Prevalent Cases of Primary Hyperoxaluria in the 7MM Download the report to understand which factors are driving Primary Hyperoxaluria epidemiology trends @ Primary Hyperoxaluria Prevalence [ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Primary Hyperoxaluria Marketed Drugs * OXLUMO (Lumasiran/ALN-GO1): Alnylam Pharma Lumasiran (formerly ALN-GO1) developed by Alnylam Pharma, approved in Year 2020, is a subcutaneously administered, RNAi therapeutic targeting glycolate oxidase (GO). Lumasiran is designed to reduce hepatic levels of GO enzyme (encoded by HAO1), thereby depleting substrate necessary for oxalate production, which directly contributes to the pathophysiology of Primary Hyperoxaluria type 1. * RIVFLOZA (nedosiran/DCR-PHXC): Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceutical's Nedosiran (formerly referred to as DCR-PHXC) is an advanced therapy utilized with the company's GalXC technology to treat patients with Primary Hyperoxaluria. It was approved in Year 2023. It inhibits the lactate dehydrogenase (LDH) enzyme in the final common step of this pathway and thereby attempts to prevent this overproduction of oxalate. This LDH enzyme inhibition occurs specifically in the liver due to the incorporation of GalNAc targeting ligands in nedosiran that bind specifically to the asialoglycoprotein receptors (ASGPR) on hepatic cell surfaces. Primary Hyperoxaluria Emerging Drugs * Stiripentol (Diacomit): Biocodex Stiripentol is an anticonvulsant drug used in treating epilepsy as an adjunct therapy along with Clobazam and Valproic acid. This drug is currently approved in the US, Canada, and European countries as oral tablets marketed as Diacomit. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates gamma-aminobutyric acid (GABA) levels, a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system. Get In-Depth Knowledge on Primary Hyperoxaluria Market Trends and Forecasts with DelveInsight @ Primary Hyperoxaluria Treatment Market [ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Primary Hyperoxaluria Market Outlook The global burden of Primary Hyperoxaluria has increased over the years. Among the seven major markets, the United States has reported having maximum diagnosed prevalent cases of Primary Hyperoxaluria. Though the prevalence of Primary Hyperoxaluria is high across the US, the condition is often misdiagnosed, ultimately leading to a lower treatable pool (when compared to the total prevalent population of the disease) that contributes to the market size of Primary Hyperoxaluria. Primary Hyperoxaluria Treatment Market The Primary Hyperoxaluria treatment usually started with citrates, vitamin B6, and hyperhydration. After that, iRNA therapies begin. Patients with advanced kidney failure go for kidney transplantation. Transplantation methods depend on the type of primary hyperoxaluria and the particular patient, but combined liver and kidney transplantation is the method of choice in patients with PH1, and isolated kidney transplantation is the preferred method with PH2. Gain a strategic edge in the Primary Hyperoxaluria Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Primary Hyperoxaluria Market Forecast. Click here to lead in advancements @ Primary Hyperoxaluria Clinical Trials Assessment [ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Scope of the Primary Hyperoxaluria Market Report * Study Period: 2020-2034 * Coverage: 7MM * Primary Hyperoxaluria Companies: Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Biocodex, Dicerna Pharmaceuticals, and others * Primary Hyperoxaluria Therapies: Nedosiran (DCR-PHXC), ALLN-177, Stiripentol, Lumasiran, stiripentol (Diacomit), DCR-PHXC, and others * Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies * Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers * Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies * Primary Hyperoxaluria Unmet Needs, KOL's views, Analyst's views, Primary Hyperoxaluria Market Access and Reimbursement Table of Contents 1. Primary Hyperoxaluria Market Report Introduction 2. Executive Summary for Primary Hyperoxaluria 3. SWOT analysis of Primary Hyperoxaluria 4. Primary Hyperoxaluria Patient Share (%) Overview at a Glance 5. Primary Hyperoxaluria Market Overview at a Glance 6. Primary Hyperoxaluria Disease Background and Overview 7. Primary Hyperoxaluria Epidemiology and Patient Population 8. Country-Specific Patient Population of Primary Hyperoxaluria 9. Primary Hyperoxaluria Current Treatment and Medical Practices 10. Primary Hyperoxaluria Unmet Needs 11. Primary Hyperoxaluria Emerging Therapies 12. Primary Hyperoxaluria Market Outlook 13. Country-Wise Primary Hyperoxaluria Market Analysis (2020-2034) 14. Primary Hyperoxaluria Market Access and Reimbursement of Therapies 15. Primary Hyperoxaluria Market Drivers 16. Primary Hyperoxaluria Market Barriers 17. Primary Hyperoxaluria Appendix 18. Primary Hyperoxaluria Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=primary-hyperoxaluria-therapeutics-market-size-in-the-7mm-was-usd-316-million-in-2023-estimated-delveinsight ] Phone: 9650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage This release was published on openPR.The speculation is at an end – Universal Pictures has announced that Christopher Nolan’s next film is an adaptation of Homer’s “The Odyssey”. In a posting on , Nolan’s take is described as a “mythic action epic shot across the world using brand new IMAX film technology.” The film brings Homer’s iconic saga of Odysseus and his many year journey home after the Trojan War to IMAX film screens for the first time. Matt Damon, Tom Holland, Zendaya, Anne Hathaway, Lupita Nyong’o and Robert Pattinson star in the film which will shoot early next year and opens in cinemas everywhere on July 17th 2026. The story has been adapted for the screen several times – as the Kirk Douglas-led film “Ulysses ” in 1954, as the early 1980s sci-fi animated series “Ulysses 31,” as a memorable TV mini-series in 1997 starring Armand Assante, and loosely turned into the Coen brothers’ “O Brother, Where Art Thou?”. The news comes as the Ralph Fiennes-led “The Return,” which adapts the last part of the story, is currently in cinemas.None
Application Hosting Market Overview: Market Share, Value, and CAGR Projections for 2024-2031Blockmate Ventures Announces Closing of Strategic Investment and Incentive Grant
VANCOUVER, BC and BREDA, THE NETHERLANDS / ACCESSWIRE / November 27, 2024 / Organto Foods Inc. (TSXV:OGO)(OTCQB:OGOFF)(FSE:OGF) ("Organto" or "the Company"), a provider of branded, private label and bulk distributed healthy and organic fruit and vegetable products today announced its financial results for the three and nine-month periods ended September 30, 2024. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted. "We are pleased with our financial results for the third quarter of 2024 which reflect the impact of our operational restructuring which has streamlined our product portfolio, shifted our marketing strategy and re-engineered our ongoing operating costs. We believe the results for the third quarter reflect the benefits of our repositioning efforts, including sales growth of 47% versus the prior year, gross profit dollar growth of 63% versus the prior year, and substantially improved bottom line results versus the prior year that are continuing to improve. Our work is not done, and we remain intently focused on leveraging the positive changes we have made as we drive continued business growth combined with operational improvements, all leading to long-term profitability and sustainability. We also continue to focus on the restructuring of our convertible debenture obligations, which is expected to result in reduced cash outlays and greater operating flexibility. We believe the impact of these initiatives will continue to be apparent as we report our results in the coming quarters." commented Steve Bromley, Chair and Chief Executive Officer. Bromley commented further, "Immediately following the filing of our Financial Statements and Management Discussion and Analysis for the second quarter of 2024, we submitted our application to have the current Cease Trade Order lifted. This process is ongoing, and we are hopeful it will be concluded in the near term. We believe we are now fully current with all financial related filings, and when combined with the performance of our restructured business, are looking forward to an exciting future. We truly appreciate the continued support we have received from our shareholders, debenture holders and key operating partners as we have worked through the restructuring of our business. We remain committed to building a world class foods company focused on serving growing global healthy foods markets with the goal of building long-term shareholder value." Third Quarter 2024 Financial Results Overview As a result of the sales of the three subsidiaries in June 2024, all sales and expenses, as well as any gains and losses relating to the operations of the sold subsidiaries have been eliminated from continuing operations and instead are shown as a single line item, loss from discontinued operations, for both the current period and any comparative historical periods. Sales of $5.2 million versus sales of $3.5 million in the prior year, an increase of 47%, driven by strong growth in sales of organic and fairtrade bananas to European customers. Gross profit of $0.6 million or 11.8% of sales versus $0.4 million or 10.6% of sales in the prior year. Third quarter gross profit includes a one-time favorable adjustment of approximately $104,000 to properly allocate sales commissions to selling, general and administration expenses for the first and second quarters of 2024. Excluding this adjustment, gross profit for the third quarter of 2024 was $0.5 million or 9.8% of sales. Cash overhead costs increased to 19% of sales versus 13% in the prior year. Third quarter 2024 costs include approximately $113,000 related to ongoing restructuring, reorganization and cease trade order activities combined with additional costs to complete the 2023 financial audit. Excluding this, the increase in ongoing costs was driven by the retention of costs and resources which were previously included in sold subsidiaries, offset by the savings realized from our efforts to streamline and simplify the business. The current quarter loss for the period was $0.8 million versus a loss of $1.6 million in the prior year, reflecting improvement as the business has been and continues to be restructured and positioned for future growth and profitability. Year to Date 2024 Financial Results Overview Sales of $14.3 million versus sales of $10.9 million in the prior year, an increase of 31%, driven by strong growth in sales of organic and fairtrade bananas to European customers. Gross profit of $1.2 million or 8.2% of sales versus $1.0 million or 9.4% of sales in the prior year, a dollar increase of 15%. Year-over-year gross profit as a percentage of sales was impacted by currency fluctuations and supply chain costs. Cash overhead costs remained flat at 14% of sales. Our third quarter 2024 included approximately $113,000 related to ongoing restructuring, reorganization and cease trade order activities combined with additional costs to complete the 2023 financial audit. These costs plus incremental costs driven by the retention of resources which were previously included in sold subsidiaries were offset by the savings realized from our efforts to streamline and simplify the business. Gain of $2.6 million on the sales of three of our wholly owned Dutch operating subsidiaries (see July 12, 2024 and June 5, 2024 news releases) as well as a gain of $0.4 million on the dissolution of an inactive subsidiary. Loss for the year of $0.3 million versus a loss of $5.9 million in the prior year, reflecting a substantial improvement as the business has been and continues to be restructured and positioned for future growth and profitability. Interested parties may access the Company's filings including Financial Statements and accompanying Management's Discussion and Analysis for the period ended September 30, 2024 at www.SEDARplus.ca or at the Company's website at www.organto.com under the Investors tab. ON BEHALF OF THE BOARD, Steve Bromley Chair and Chief Executive Officer Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. For more information contact: Investor Relations info@organto.com John Rathwell, Senior Vice President, Corporate Development and Investor Relations 647 629 0018 ABOUT ORGANTO Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto's business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders. FORWARD-LOOKING STATEMENTS This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). In particular, and without limitation, this news release contains forward-looking statements respecting Organto's business model and markets; Organto's belief that the Company has made good progress in the restructuring of its business and is focused on a clear path to profitability; Organto's belief that its efforts to restructure its convertible debt portfolio is expected to result in reduced debt levels and greater operating flexibility; Organto's belief that as it is now current with its filing obligations and believe that its application to have the current Cease Trade Order revoked as per the terms of securities legislation of British Columbia will be concluded in the near term; Organto's belief that it remains focused on building a world class company focused on growing healthy foods markets with the goal of building long-term shareholder value; management's beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto's business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law. SOURCE: Organto Foods, Inc. View the original on accesswire.comUkraine Supports Stabilizing Syria, Zelenskiy Says As He Again Warns Of Russia-North Korea Cooperation
SANTA CRUZ, Calif. (AP) — Two people were rescued when a California pier under construction partially collapsed and fell into the ocean Monday as the state's central coast was pounded by heavy surf from a major storm expected to bring hurricane-force winds to the seas off the Pacific Northwest, authorities said. Residents were warned to stay away from low-lying areas near the beaches around the Santa Cruz Wharf, about 70 miles (112 kilometers) south of San Francisco, as the storm rapidly gained strength. “You are risking your life, and those of the people that would need to try and save you by getting in or too close to the water,” the National Weather Service's Bay Area office said on the social platform X. Lifeguards rescued two people from the water and a third person was able to swim to safety, officials with Santa Cruz Fire Department said. No one had serious injuries, Mayor Fred Keeley said. The mayor said the section of the wharf that collapsed had been damaged over time. The structure was in the middle of a $4 million renovation following destructive storms last winter. Tony Elliot, the head of the Santa Cruz Parks & Recreation Department, estimated that about 150 feet (45 meters) of the end of the wharf fell into the water around 12:45 p.m. It was immediately evacuated and will remain closed indefinitely. Some of the wharf’s pilings are still in the ocean and remain “serious, serious hazards” to boats, the mayor said. Each piling weighs hundreds of pounds and is being pushed by powerful waves. Gov. Gavin Newsom's has been briefed and the state's Office of Emergency Services is coordinating with local officials, his office said. Forecasters warned that storm swells will continue to increase throughout the day. “We are anticipating that what is coming toward us is more serious than what was there this morning,” the mayor said. Ocean swells along California's central coast could reach 60 feet (18 meters) as the Pacific storm gains strength through Monday, the weather service said. “A rapidly developing storm will bring hurricane force winds to the areas well offshore of the Pacific Northwest tonight,” the weather service's Ocean Prediction Center said on X. Winds off Oregon and Washington could peak near 80 mph (130 kph) and seas will build over 30 feet (9.1 meters), forecasters said. The end of the pier that broke off had been shut down during renovations. The portion, which included public restrooms and the closed Dolphin restaurant, floated about half a mile (0.8 kilometers) down the coast and wedged itself at the bottom of the San Lorenzo River. Those who fell into the water were two engineers and a project manager who were inspecting the end of the wharf, officials said. No members of the public were in the area. Building inspectors were now looking at the rest of the Santa Cruz Wharf’s structural integrity. Monday's collapse came about a year after the Seacliff State Beach pier just down the coast was battered beyond repair by a heavy winter storm. ___ Dazio reported from Los Angeles. Best trending stories from the week. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. You may occasionally receive promotions exclusive discounted subscription offers from the Roswell Daily Record. Feel free to cancel any time via the unsubscribe link in the newsletter you received. You can also control your newsletter options via your user dashboard by signing in.